This biobank focuses on:

• Establishment of the Human Bioresource Bank that will collect and provide human specimens containing high-risk viruses/antigens/antibodies/nucleic acids to the biomedical research and industry communities
• Establishment of the Customized Pathogen Culture Collection that will collect and distribute pathogens based on the needs of researchers studying new and emerging infections
• Production of Standardized Bioresources for quality assurance of biological medicines and diagnostics
• Education and Training opportunities for the diverse needs of researchers who are not familiar with the field but want to conduct infectious bioresources-based research

The Animal Research Lab (ANL) is responsible for designing animal experiment models for various diseases and conducting in vivo experiments to investigate the efficacy of infectious disease vaccines and therapeutic candidates. ANL also conducts preclinical research on animal experiments to evaluate the practical use of the results obtained through basic and translational research at IPK. In particular, ANL establishes new drug candidate evaluation platforms and manages the welfare and housing of research animals.

The Animal Research Lab capabilities/assets includes:

• Establishing infectious disease animal models
• Generating animal models for human diseases utilizing state-of-the-art technologies, enabling research collaboration in the field of biomedical research
• Performing in vivo efficacy/toxicity studies
• Developing technologies for the quality control of the laboratory animals and generating genetically engineered mice (GEM)
• In total, over 550 m² (5,920 ft²) of dedicated animal space
  • Specific pathogen free (SPF) zone
  • Animal biosafety level-2, 3 laboratories
• Trained veterinary staff provide expertise in animal husbandry, transgenic mouse breeding colony maintenance and assistance with routine technical procedures
• Adhering to AAALAC International (the Association for Assessment and Accreditation of Laboratory Animal Care International) standards in order to demonstrate commitment to humane and responsible animal research and dedication to good science.

The Medicinal Chemistry team focuses on the optimization of compounds which are identified as effective against target diseases through primary screening.

The areas of activity include:

• Advancing and accelerating the optimization on drug discovery program
• Developing novel chemical platform technology for innovative drug discovery (Establishment of PROTAC platform)
• Developing probe molecules for identifying target and understanding the in vivo mechanism of drug candidates
• Developing tool compounds for monitoring drug localization in either the cell or living animal
• Provide open analytical chemistry services, synthesis know-hows and molecular modeling analysis by giving access to IPK’s well-equipped infrastructure to support academia and pharmaceutical companies.

The Screening Discovery Platform (SDP) provides expertise in the drug discovery pipeline for assay development and high-throughput screening. We have automated Screening Platforms in BSL2+ (Opera Phenix Plus, Operetta CLS, Ensight, Envision) / BSL3 (Operetta CLS, Nivo) to support research activities.

All types of assay models (phenotypic, target, 3D) can be run against our libraries for drug repositioning, new chemical entities, target ID, and MOA assessment.

• Validating and formatting assays to 96/384/1536 well format to perform screening activities
• Chemical library collection of 400K compounds identified as potential starting points for the development of novel therapeutics
• Genomic platforms (siRNA and shRNA technology) to identify new targets and signaling pathways as well as uncover mechanism of actions
• Advanced liquid handlers to support any workflow processes including Echo Acoustic Dispenser, Biomek, and Janus.

Development areas: High Throughput Screening, High Content Screening, Small Molecule, Drugs, Functional Genomics, Target ID & MOA, Ai-driven analysis.

Our objective is to create customized, cost-effective tool and instrument utilizing readily available technology to address scientific needs. Once you reach out to us, we will arrange a teleconference meeting to delve into the project. Subsequently, we will engage in an iterative interaction, progressing from the initial design concept to the actual creation of the tool or instrument. This comprehensive approach may span several months to ensure a successful and satisfying outcome

Our platform facilitates the exploration of protein-protein interactions (PPI) within living cells, utilizing a diverse range of high-throughput methods. We harness the power of the Bioluminescence Resonance Energy Transfer (BRET) technique for the precise quantification of proteins of interest, including, for example, pathogen/host protein pairs. What distinguishes our method is its capability to continuously monitor these interactions in real time within living cells for extended durations. This versatile approach supports a wide array of applications, including PPI validation, time-lapse PPI cell quantification, assessment of affinity in mutant PPI pairs, PPI competition studies, and screening for PPI modulators in drug discovery.